Basic HTML Version
67
Arkadiusz Niklas, Andrzej Tykarski,
Sympozjum EXTEND-
Thrombosis Expert Forum
www.chsin.viamedica.pl
40. Otten H.M., Mathijssen J., ten Cate H. i wsp. Symptomatic venous thrombo-
embolism in cancer patients treated with chemotherapy: an underestimated
phenomenon.
Arch. Intern. Med.
2004; 164: 190–194.
41. Heit J.A., Silverstein M.D., Mohr D.N., Petterson T.M., O’Fallon W.M., Mel-
ton L.J. 3rd. Risk factors for deep vein thrombosis and pulmonary em-
bolism: a population-based case-control study.
Arch. Intern. Med.
2000;
160: 809–815.
42. Heit J.A., Mohr D.N., Silverstein M.D., Petterson T.M, O’Fallon W.M., Mel-
ton L.J. 3rd. Predictors of recurrence after deep vein thrombosis and pul-
monary embolism: a population-based cohort study.
Arch. Intern. Med.
2000; 160: 761–768.
43. Mandalà M., Falanga A., Roila F.; ESMO Guidelines Working Group. Venous
thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for
the management.
Ann. Oncol.
2010; 21 (supl. 5): V274–V276.
44. NCCNguidelines 2011: www.nccn.org/professionals/physician_gls/pdf/vte.pdf.
45. Agnelli G., Gussoni G., Bianchini C. i wsp.; PROTECHT Investigators. Nad-
roparin for the prevention of thromboembolic events in ambulatory patients
with metastatic or locally advanced solid cancer receiving chemotherapy:
a randomised, placebo-controlled, double-blind study.
Lancet Oncol.
2009;
10: 943–949.
46. Lee A.Y., Levine M.N., Baker R.I. i wsp.; Randomized Comparison of Low-
-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Pre-
vention of Recurrent Venous Thromboembolism in Patients with Cancer
(CLOT) Investigators. Low-molecular-weight heparin versus a coumarin
for the prevention of recurrent venous thromboembolism in patients with
cancer.
N. Engl. J. Med.
2003; 349: 146–153.
47. Kakkar A.K., Levine M., Pinedo H.M. i wsp. Venous thrombosis in cancer
patients: Insights from the FRONTLINE survey.
Oncologist
2003; 8
:
381–
388.